BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp.

<< Previous

Bullboard Posts

Next >>

Post by frankmanon Nov 13, 2024 2:39pm

37 Views

Post# 36310860

1.7 million shares traded 3 million in 3 days-consolidation

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr
C ATS	50.1	0.065	·	0.07	63.0	0.07	+0.005	7.7	1,762.4	106	163
CSE - C	50.1	0.065	·	0.07	63.0	0.07	+0.005	7.7	885.0	53	72
NEO ATS - U						0.065			65.0	3	14
Omega - O						0.065			442.0	28	31
Chi-X - X						0.065			1.0		1
CX2 - H						0.065			316.1	19	29
CXD - D						0.0575	-0.0075	-11.5	5.9	0	7
TriAct - M						0.065			47.4	2	9